Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 397.74M P/E - EPS this Y 20.20% Ern Qtrly Grth -
Income -138.24M Forward P/E -2.75 EPS next Y 8.30% 50D Avg Chg -14.00%
Sales 73.62M PEG - EPS past 5Y -10.60% 200D Avg Chg -51.00%
Dividend N/A Price/Book 1.48 EPS next 5Y - 52W High Chg -75.00%
Recommedations 2.50 Quick Ratio 6.04 Shares Outstanding 21.16M 52W Low Chg 5.00%
Insider Own 6.10% ROA -22.89% Shares Float 13.34M Beta 0.49
Inst Own 99.89% ROE -56.11% Shares Shorted/Prior 2.74M/2.41M Price 18.89
Gross Margin 100.00% Profit Margin -187.77% Avg. Volume 235,648 Target Price 22.29
Oper. Margin -193.78% Earnings Date May 6 Volume 143,399 Change 1.34%
About Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals, Inc. News
04:47 PM Enanta Pharmaceuticals Reports Fiscal Q2 Results: A Closer Look Against Analyst Expectations
04:10 PM Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
03:01 PM Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET
05/03/24 Strong week for Enanta Pharmaceuticals (NASDAQ:ENTA) shareholders doesn't alleviate pain of five-year loss
04/30/24 Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/30/24 Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
04/29/24 Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024
04/17/24 Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
07:00 AM Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference
02/12/24 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
02/08/24 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2024 Earnings Call Transcript
02/08/24 Q1 2024 Enanta Pharmaceuticals Inc Earnings Call
02/07/24 Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
02/07/24 Enanta Pharmaceuticals Inc (ENTA) Reports Fiscal Q1 2024 Results: Royalty Revenue Declines Amid ...
02/07/24 Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET
07:00 AM Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
01/31/24 Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023
01/05/24 Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
01/04/24 Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference
01/03/24 Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
ENTA Chatroom

User Image epsguid Posted - 3 hours ago

$ENTA reported a loss of $1.47, consensus was ($1.26) via @eWhispers #epsmiss http://eps.sh/d/enta

User Image DonCorleone77 Posted - 3 hours ago

$enta Enanta reports Q2 EPS ($1.47), consensus ($1.33) Reports Q2 revenue $17.1M, consensus $16.52M. "At Enanta, we are committed to advancing the first antiviral treatment for RSV, and more broadly developing important medicines in virology and immunology. Our commitment is highlighted by our goal to deliver multiple RSV data readouts this year, including from our challenge study of EDP-323, an oral L-protein inhibitor, expected in the third quarter, and from RSVPEDs, our Phase 2 pediatric study of zelicapavir, an oral N-protein inhibitor. In RSVPEDs, we are nearing study completion and are now only enrolling patients aged 28 days to 6 months, which is the last age cohort in Part 2. As this narrows the eligible patient population, we will continue recruiting in the Southern Hemisphere and anticipate reporting data from this study in the second half of 2024," said Jay R. Luly, Ph.D., President and Chief Executive Officer at Enanta Pharmaceuticals. "Pending positive data from these studies, we will be poised to deliver potential first-in-class antiviral replication inhibitors with differentiated mechanisms of action and advance our robust RSV portfolio. Beyond RSV, we are eager to help patients affected by CSU, a severely debilitating inflammatory skin disease, with our first immunology program focused on developing oral KIT inhibitors. We are on track to select a KIT inhibitor development candidate in the fourth quarter and look forward to expanding more broadly into immune-mediated chronic diseases with a second program this year."

User Image Stock_Titan Posted - 3 hours ago

$ENTA Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET https://www.stocktitan.net/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-kyag64yz9u4z.html

User Image Stock_Titan Posted - 04/30/24

$ENTA Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/ENTA/enanta-pharmaceuticals-announces-inducement-grants-under-nasdaq-ock9aayo9ims.html

User Image Stock_Titan Posted - 04/29/24

$ENTA Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024 https://www.stocktitan.net/news/ENTA/enanta-pharmaceuticals-to-host-conference-call-on-may-6-at-4-30-p-m-wz2zal1rbmf3.html

User Image Aigner_Andreas Posted - 04/17/24

TF SELL $ENTA at 14 : 14.38 SmallCap 44% Shp 0.92 S 4.29 N 0.77 RSI 38.72% SRSI 0% ADXR 21.54 #stocks #trading #finance #market

User Image fda_tracker Posted - 04/17/24

$ENTA Phase 2 trial w/est Apr completion date NCT05568706: https://www.clinicaltrials.gov/study/NCT05568706 Trial Tracker: https://www.fdatracker.com/trial-tracker/

User Image Stock_Titan Posted - 04/17/24

$ENTA Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 https://www.stocktitan.net/news/ENTA/enanta-pharmaceuticals-announces-data-presentation-at-escmid-global-w7m1cvovng7a.html

User Image fda_tracker Posted - 04/16/24

$ENTA Phase 2 trial w/est Apr completion date NCT04816721: https://www.clinicaltrials.gov/study/NCT04816721 Trial Tracker: https://www.fdatracker.com/trial-tracker/

User Image Bigeyes2 Posted - 03/27/24

$ENTA Inverted head and shoulders on the hourly chart

User Image MargaretMurphey344 Posted - 03/26/24

$ENTA STLNF's tech in uranium extraction could be a game-changer. Watching closely.

User Image Stock_Titan Posted - 2 months ago

$ENTA Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference https://www.stocktitan.net/news/ENTA/enanta-pharmaceuticals-to-participate-at-leerink-partners-global-hzv917yj9vcp.html

User Image lukustra Posted - 02/20/24

$ENTA should see a move higher

User Image epsguid Posted - 02/07/24

$ENTA reported a loss of $1.58, consensus was ($1.18) via @eWhispers #epsmiss http://eps.sh/d/enta

User Image Stock_Titan Posted - 02/07/24

$ENTA Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET https://www.stocktitan.net/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-xhky9l5x175x.html

User Image Stock_Titan Posted - 3 months ago

$ENTA Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference https://www.stocktitan.net/news/ENTA/enanta-pharmaceuticals-to-participate-at-the-oppenheimer-34th-annual-2qgszwpx22ng.html

User Image cctranscripts Posted - 01/22/24

Statement of acquisition of beneficial ownership by individuals https://www.conferencecalltranscripts.org/summary/?id=12883257 $ENTA

User Image tickeron Posted - 01/21/24

What do you think of this? $ENTA entered a Downtrend because Momentum Indicator dropped below the 0 level. View odds of downtrend. https://srnk.us/go/4974427

User Image WallStArb Posted - 01/19/24

$ASMB interesting pullback from last week and now the buyer causing the spikes in volume and price for the last 2 weeks will likely own over 15% after today. Curious how/if this reacts to a reverse split if it happens. I have a position in a few cash rich antivirals including $AVIR and $ENTA.

User Image chart_tradr Posted - 01/19/24

$ENTA Its getting ready for the move much much higher... Me thinks...

User Image quantcha Posted - 01/13/24

StockTwits Trending Alert: Trading recent interest in ENANTA PHARMACEUTICALS INC. C $ENTA https://ideas.quantcha.com/?p=78043

User Image tickeron Posted - 01/13/24

$ENTA enters bullish trend https://srnk.us/go/4968014

User Image tickeron Posted - 01/12/24

$ENTA enters bullish trend https://srnk.us/go/4966637

User Image cctranscripts Posted - 01/11/24

Israel A. Englander just provided an update on share ownership of Enanta Pharmaceuticals Inc https://www.conferencecalltranscripts.org/summary/?id=12860953 $ENTA

User Image tickeron Posted - 01/11/24

$ENTA enters bullish trend https://srnk.us/go/4965671

User Image StockAutomatePro Posted - 01/10/24

$ENTA Stock market is looking optimistic based on the chart. We alerted the BUY signal at $9.72 and we were able to close this one with profit at $11.84 🎯

User Image tickeron Posted - 01/10/24

$ENTA enters bullish trend https://srnk.us/go/4964741

User Image StockAutomatePro Posted - 01/08/24

$ENTA The chart suggests a bullish outlook for the stock. We alerted the BUY signal at $9.77 and we were able to close this one with profit at $12.46 💯

User Image UltraAlgo Posted - 01/08/24

$ENTA Sell Rating based off 4 signals, 15-min chart. 💸 Algo Trading at UltraAlgo https://i.redd.it/dtl53dpucbac1.png

User Image The_Hyneman Posted - 01/07/24

$ENTA 👀 jack-in-the-box bullish, may work its way up the right side of the bowl to 14 this week if continuation happens 20M float (Finviz)

Analyst Ratings
JP Morgan Underweight Feb 8, 24
Oppenheimer Perform Nov 22, 23
HC Wainwright & Co. Buy Nov 21, 23
JMP Securities Outperform Nov 21, 23
HC Wainwright & Co. Buy Oct 23, 23
RBC Capital Sector Perform Oct 2, 23
HC Wainwright & Co. Buy Sep 19, 23
Oppenheimer Perform Aug 9, 23
HC Wainwright & Co. Buy Aug 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Vance Terry Director Director Dec 13 Sell 9.12 15,295 139,490 5,800 12/15/23
Luu Brendan Sr. VP, Business Dev.. Sr. VP, Business Dev. Dec 05 Sell 9.63 2,125 20,464 36,736 12/06/23
Kieffer Tara Lynn Sr. VP, New Prod. St.. Sr. VP, New Prod. Strat. & Dev Dec 05 Sell 9.63 2,125 20,464 37,260 12/06/23
Gardiner Nathaniel S. Sr. VP & General Cou.. Sr. VP & General Counsel Dec 05 Sell 9.63 2,412 23,228 68,154 12/06/23
Rottinghaus Scott T. Sr. VP & CMO Sr. VP & CMO Dec 05 Sell 9.63 534 5,142 26,466 12/06/23
Or Yat Sun Sr. VP, R&D & CSO Sr. VP, R&D & CSO Dec 05 Sell 9.63 2,412 23,228 370,695 12/06/23
MELLETT PAUL J Sr. VP, Finance & Ad.. Sr. VP, Finance & Admin. & CFO Dec 05 Sell 9.63 2,412 23,228 93,549 12/06/23
Luly Jay R. President and CEO President and CEO Dec 05 Sell 9.63 7,230 69,625 806,793 12/06/23
Gardiner Nathaniel S. Sr. VP & General Cou.. Sr. VP & General Counsel Apr 18 Option 30 6,667 200,010 79,980 04/19/23
Vance Terry Director Director Mar 16 Option 14 5,800 81,200 21,095 03/17/23
MELLETT PAUL J Treasurer and CFO Treasurer and CFO Mar 15 Sell 44.2 10,440 461,448 97,556 03/17/23
MELLETT PAUL J Treasurer and CFO Treasurer and CFO Mar 15 Option 14 10,440 146,160 107,996 03/17/23
Or Yat Sun Sr. VP & CSO Sr. VP & CSO Mar 15 Sell 44.19 13,925 615,346 374,702 03/17/23
Or Yat Sun Sr. VP & CSO Sr. VP & CSO Mar 15 Option 14 13,925 194,950 388,627 03/17/23
Luly Jay R. President and CEO President and CEO Mar 13 Sell 45.42 27,912 1,267,763 819,810 03/14/23
Luly Jay R. President and CEO President and CEO Mar 13 Option 14 27,912 390,768 847,722 03/14/23
MELLETT PAUL J Treasurer and CFO Treasurer and CFO Feb 09 Sell 54.03 5,000 270,150 83,463 02/13/23
MELLETT PAUL J Treasurer and CFO Treasurer and CFO Jan 09 Option 14.18 2,812 39,874 88,463 01/10/23
MELLETT PAUL J Treasurer and CFO Treasurer and CFO Dec 19 Option 14.18 4,148 58,819 85,651 12/19/22
Luly Jay R. President and CEO President and CEO Dec 19 Option 27.58 14,500 399,910 788,305 12/19/22
Luly Jay R. President and CEO President and CEO Dec 16 Option 14.09 30,000 422,700 803,805 12/16/22
Luly Jay R. President and CEO President and CEO Dec 16 Sell 44.54 30,000 1,336,200 773,805 12/16/22
Adda Nathalie Sr. VP & Chief Medic.. Sr. VP & Chief Medical Officer Apr 01 Option 44.23 83,344 3,686,305 67,767 04/05/22
Adda Nathalie Sr. VP & Chief Medic.. Sr. VP & Chief Medical Officer Apr 01 Sell 71.74 83,344 5,979,099 34,982 04/05/22
CARTER BRUCE L A Director Director Mar 21 Option 25.58 6,000 153,480 6,000 03/22/22
CARTER BRUCE L A Director Director Mar 21 Sell 68.03 6,000 408,180 03/22/22
Adda Nathalie Sr. VP & Chief Medic.. Sr. VP & Chief Medical Officer Mar 01 Option 43.46 36,820 1,600,197 47,463 03/03/22
Adda Nathalie Sr. VP & Chief Medic.. Sr. VP & Chief Medical Officer Mar 01 Sell 70.46 36,820 2,594,337 34,982 03/03/22
Luly Jay R. President and CEO President and CEO Jan 15 Option 11.77 10,063 118,442 710,791 01/18/22
Adda Nathalie Sr. VP & Chief Medic.. Sr. VP & Chief Medical Officer Jan 11 Option 36.73 12,536 460,447 45,438 01/13/22
Adda Nathalie Sr. VP & Chief Medic.. Sr. VP & Chief Medical Officer Jan 11 Sell 70.13 12,536 879,150 32,902 01/13/22
Adda Nathalie Sr. VP & Chief Medic.. Sr. VP & Chief Medical Officer Nov 01 Option 48.52 9,547 463,220 36,491 11/02/21
Adda Nathalie Sr. VP & Chief Medic.. Sr. VP & Chief Medical Officer Nov 01 Sell 85.18 9,547 813,213 26,944 11/02/21
Adda Nathalie Sr. VP & Chief Medic.. Sr. VP & Chief Medical Officer Oct 08 Option 43.46 17,500 760,550 30,991 10/13/21
Adda Nathalie Sr. VP & Chief Medic.. Sr. VP & Chief Medical Officer Oct 08 Sell 70.22 17,500 1,228,850 26,944 10/13/21